FDG-PET positive pilomatrixoma — reconsidering multicentricity in Langerhans cell histiocytosis

We report a case of a woman who underwent a curative resection of an upper jaw tumor histologically verified as eosinophilic granuloma. To exclude possible multiorgan involvement, PET/CT imaging was performed and revealed a metabolically active, partially calcified lesion located on the chest wall surface and clinically corresponding to a gradually developing, round, subcutaneous infiltrate with erythematous overlying skin. After complete extirpation, the pathological finding was consistent with pilomatrixoma surprisingly, thus dismissing the suspected diagnosis of multi-system Langerhans cell histiocytosis

Commission des Communautes Europeennes: Groupe du Porte-Parole. Reunion de la Commission du mercredi 29 octobre 1980 = Commission of European Communities: Spokesman Group. Meeting of the Commission on Wednesday, 29 October 1980. Spokesman Service Note to National Offices Bio No. (80) 432, 30 October 1980

We study strong-field ionization and rescattering beyond the long-wavelength limit of the dipole approximation with elliptically polarized mid-IR laser pulses. Full three-dimensional photoelectron momentum distributions (PMDs) measured with velocity map imaging and tomographic reconstruction revealed an unexpected sharp ridge structure in the polarization plane (2018 Phys. Rev. A 97 013404). This thin line-shaped ridge structure for low-energy photoelectrons is correlated with the ellipticity-dependent asymmetry of the PMD along the beam propagation direction. The peak of the projection of the PMD onto the beam propagation axis is shifted from negative to positive values when the sharp ridge fades away with increasing ellipticity. With classical trajectory Monte Carlo simulations and analytical analysis, we study the underlying physics of this feature. The underlying physics is based on the interplay between the lateral drift of the ionized electron, the laser magnetic field induced drift in the laser propagation direction, and Coulomb focusing. To apply our observations to emerging techniques relying on strong-field ionization processes, including time-resolved holography and molecular imaging, we present a detailed classical trajectory-based analysis of our observations. The analysis leads to the explanation of the fine structure of the ridge and its non-dipole behavior upon rescattering while introducing restrictions on the ellipticity. These restrictions as well as the ionization and recollision phases provide additional observables to gain information on the timing of the ionization and recollision process and non-dipole properties of the ionization process.ISSN:1361-6455ISSN:0368-3508ISSN:0953-4075ISSN:0022-370

Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma

Pulmonary Langerhans cell histiocytosis (PLCH) is a rare cause of interstitial lung disease characterized by formation of nodules in the active phase of the disease that evolve into nonactive cystic lesions later on. To evaluate PLCH activity in patients, we developed a new method for measuring diffuse metabolic activity on fluorine-18-fluorodeoxyglucose positron emission tomography/ computed tomography (FDG-PET/CT) using a lung-to-liver activity ratio. Material and Methods: We retrospectively studied a series of 4 FDG-PET and 23 FDG-PET/CT scans from 7 patients with PLCH and analyzed a sample of 100 randomly chosen FDG-PET/CT studies free from any known lung or hepatic diseases. Maximum standardized uptake value (SUVmax) in a spherical volume (6–8 cm in diameter) in the right lung was put into relation with SUVmax in a spherical volume (9–10 cm in diameter) in the reference liver parenchyma to set up the SUVmaxPULMO/SUVmaxHEPAR index. The index values were compared to the disease course in each patient. Results: In patients with PLCH, a close correlation between the index value and the disease course was found in all seven subjects, where the increasing index values indicated disease activity, while decreasing index values were observed after therapy administration. In the group of 100 healthy control subjects, we found index values lower than 0.3 in 80% and lower than 0.4 in 96%. Conclusion: Measuring SUVmaxPULMO/SUVmaxHEPAR values and their time-trend monitoring represent simple, noninvasive screening tools allowing an early diagnosis and treatment response follow-up assessment in patients with PLCH

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

Purpose: We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term efficacy and safety outcomes of patients with chronic myeloid leukemia (CML) in chronic phase (CP) treated with dasatinib or imatinib. Patients and Methods: Patients with newly diagnosed CML-CP were randomly assigned to receive dasatinib 100 mg once daily (n = 259) or imatinib 400 mg once daily (n = 260). Results: At the time of study closure, 61% and 63% of dasatinib- and imatinib-treated patients remained on initial therapy, respectively. Cumulative rates of major molecular response and molecular responses with a 4.0- or 4.5-log reduction in BCR-ABL1 transcripts from baseline by 5 years remained statistically significantly higher for dasatinib compared with imatinib. Rates for progression-free and overall survival at 5 years remained high and similar across treatment arms. In patients who achieved BCR-ABL1 <= 10% at 3 months (dasatinib, 84%; imatinib, 64%), improvements in progression-free and overall survival and lower rates of transformation to accelerated/blast phase were reported compared with patients with BCR-ABL1 greater than 10% at 3 months. Transformation to accelerated/blast phase occurred in 5% and 7% of patients in the dasatinib and imatinib arms, respectively. Fifteen dasatinib-treated and 19 imatinib-treated patients had BCR-ABL1 mutations identified at discontinuation. There were no new or unexpected adverse events identified in either treatment arm, and pleural effusion was the only drug-related, nonhematologic adverse event reported more frequently with dasatinib (28% v 0.8% with imatinib). First occurrences of pleural effusion were reported with dasatinib, with the highest incidence in year 1. Arterial ischemic events were uncommon in both treatment arms. Conclusion: These final results from the DASISION trial continue to support dasatinib 100 mg once daily as a safe and effective first-line therapy for the long-term treatment of CML-CP

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma

Background: the proteasome inhibitor bortezomib was initially approved for the treatment of relapsed mantle-cell lymphoma. We investigated whether substituting bortezomib for vincristine in frontline therapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) could improve outcomes in patients with newly diagnosed mantle-cell lymphoma. Methods: in this phase 3 trial, we randomly assigned 487 adults with newly diagnosed mantle-cell lymphoma who were ineligible or not considered for stem-cell transplantation to receive six to eight 21-day cycles of R-CHOP intravenously on day 1 (with prednisone administered orally on days 1 to 5) or VR-CAP (R-CHOP regimen, but replacing vincristine with bortezomib at a dose of 1.3 mg per square meter of body-surface area on days 1, 4, 8, and 11). The primary end point was progression-free survival. Results: after a median follow-up of 40 months, median progression-free survival (according to independent radiologic review) was 14.4 months in the R-CHOP group versus 24.7 months in the VR-CAP group (hazard ratio favoring the VR-CAP group, 0.63; P<0.001), a relative improvement of 59%. On the basis of investigator assessment, the median durations of progression-free survival were 16.1 months and 30.7 months, respectively (hazard ratio, 0.51; P<0.001), a relative improvement of 96%. Secondary end points were consistently improved in the VR-CAP group, including the complete response rate (42% vs. 53%), the median duration of complete response (18.0 months vs. 42.1 months), the median treatment-free interval (20.5 months vs. 40.6 months), and the 4-year overall survival rate (54% vs. 64%). Rates of neutropenia and thrombocytopenia were higher in the VR-CAP group. Conclusions: VR-CAP was more effective than R-CHOP in patients with newly diagnosed mantle-cell lymphoma but at the cost of increased hematologic toxicity. (Funded by Janssen Research and Development and Millennium Pharmaceuticals; LYM-3002 ClinicalTrials.gov number, NCT00722137)

Chemistry and Sr–Nd isotope signature of amphiboles of the magnesio-hastingsite-pargasite-kaersutite series in Cenozoic volcanic rocks: Insight into lithospheric mantle beneath the Bohemian Massif

Amphibole phenocrysts and xenocrysts from Cenozoic volcanic rocks of the Bohemian Massif (BM) belong to the magnesio-hastingsite-pargasite-kaersutite series. Their host rocks are mostly basaltic lavas, dykes and breccia pipe fills, less commonly also felsic rocks from rift zones along lithospheric block boundaries of the BM. The calculated p–T conditions suggest that almost all amphiboles crystallized in a relatively narrow temperature range (1020–1100 °C) at depths of 20–45 km (0.7–1.2 GPa) during the magma ascent. The initial 143Nd/144Nd and 87Sr/86Sr ratios of amphiboles (0.51266–0.51281 and 0.70328–0.70407, respectively) are similar to those of their whole rocks (0.51266–0.51288 and 0.70341–0.70462, respectively). This testifies to locally elevated proportions of recycled Variscan crustal material during melting of mantle peridotites rich in clinopyroxene–amphibole veins. These veins were formed by metasomatic fluids enriched in High Field Strength Elements and are isotopically similar to EM-1 mantle type.Fenokrysty a xenokrysty amfibolů kenozoických vulkanických hornin Českého masivu (ČM) náleží svým složením do magnesiohastingsit-pargasit-kaersutitové série. Jejich hostitelské horniny jsou především bazaltické lávy, žíly nebo brekciovité výplně komínů, méně často také felsické horniny z riftových zón podél hranic litosférických bloků ČM. Vypočtené p-T podmínky ukazují, že téměř všechny amfiboly krystalizovaly v relativně úzkém teplotním rozmezí (1020–1100 °C) v hloubkách 20–45 km (0,7–1,2 GPa) během výstupu magmatu. Iniciální izotopové poměry 143Nd/144Nd a 87Sr/86Sr v amfibolech jsou v rozmezí 0,51266–0,51281 a 0,70328–0,70407. To vypovídá o lokálně zvýšeném množství recyklovaného variského korového materiálu během tavení plášťového peridotitu bohatého na klinopyroxen-amfibolové žíly. Tyto žíly vznikly z metasomatických fluid obohacených o prvky s velkým iontovým potenciálem a jsou izotopově podobné obohacenému plášti typu 1 (EM-1)